Denali Therapeutics Statistics
Total Valuation
DNLI has a market cap or net worth of $2.96 billion. The enterprise value is $2.05 billion.
Important Dates
The next estimated earnings date is Wednesday, May 6, 2026, after market close.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DNLI has 158.68 million shares outstanding. The number of shares has increased by 4.97% in one year.
| Current Share Class | 158.68M |
| Shares Outstanding | 158.68M |
| Shares Change (YoY) | +4.97% |
| Shares Change (QoQ) | +1.76% |
| Owned by Insiders (%) | 4.59% |
| Owned by Institutions (%) | 97.28% |
| Float | 144.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 131.91 |
| PB Ratio | 2.82 |
| P/TBV Ratio | 2.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.16, with a Debt / Equity ratio of 0.04.
| Current Ratio | 9.16 |
| Quick Ratio | 8.85 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -45.69% and return on invested capital (ROIC) is -357.54%.
| Return on Equity (ROE) | -45.69% |
| Return on Assets (ROA) | -27.56% |
| Return on Invested Capital (ROIC) | -357.54% |
| Return on Capital Employed (ROCE) | -53.07% |
| Weighted Average Cost of Capital (WACC) | 10.13% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.02M |
| Employee Count | 503 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, DNLI has paid $102,000 in taxes.
| Income Tax | 102,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +15.57% in the last 52 weeks. The beta is 1.10, so DNLI's price volatility has been similar to the market average.
| Beta (5Y) | 1.10 |
| 52-Week Price Change | +15.57% |
| 50-Day Moving Average | 20.18 |
| 200-Day Moving Average | 17.47 |
| Relative Strength Index (RSI) | 44.95 |
| Average Volume (20 Days) | 1,400,603 |
Short Selling Information
The latest short interest is 15.28 million, so 9.63% of the outstanding shares have been sold short.
| Short Interest | 15.28M |
| Short Previous Month | 15.42M |
| Short % of Shares Out | 9.63% |
| Short % of Float | 10.60% |
| Short Ratio (days to cover) | 7.98 |
Income Statement
| Revenue | n/a |
| Gross Profit | -418.78M |
| Operating Income | -555.34M |
| Pretax Income | -512.44M |
| Net Income | -512.54M |
| EBITDA | -540.53M |
| EBIT | -555.34M |
| Earnings Per Share (EPS) | -$2.97 |
Full Income StatementBalance Sheet
The company has $867.88 million in cash and $42.29 million in debt, with a net cash position of $923.91 million or $5.82 per share.
| Cash & Cash Equivalents | 867.88M |
| Total Debt | 42.29M |
| Net Cash | 923.91M |
| Net Cash Per Share | $5.82 |
| Equity (Book Value) | 1.01B |
| Book Value Per Share | 6.49 |
| Working Capital | 802.31M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$412.60 million and capital expenditures -$9.50 million, giving a free cash flow of -$422.10 million.
| Operating Cash Flow | -412.60M |
| Capital Expenditures | -9.50M |
| Depreciation & Amortization | 14.81M |
| Net Borrowing | -8.17M |
| Free Cash Flow | -422.10M |
| FCF Per Share | -$2.66 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DNLI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.97% |
| Shareholder Yield | -4.97% |
| Earnings Yield | -17.25% |
| FCF Yield | -14.20% |
Analyst Forecast
The average price target for DNLI is $34.33, which is 84.17% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $34.33 |
| Price Target Difference | 84.17% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
